Quick navigation menu :

  1. Go to the content
  2. Go to the main sections menu
  3. Go to the search engine
  4. Go to the languages menu
  5. Go to the help menu
  6. Go to the modules
  7. Go to the shortcuts list

Help menu :

  1. Sanofi Worldwide |
     
  2. Canadian Web Sites |
     
  3. Global Business Websites |
     
  4. Contact us |
  5. Sitemap |
  6. Help
  1. RSS
  2. Font size

    Reduce font size Increase font size  
 
 

Media Room

Contact us

Sanofi Canada

2905 Place Louis-R.-Renaud
Laval, Quebec, H7V 0A3

Media inquiries

514-856-3860
Toll-free: 1-877-904-2667

Catherine Cunningham

Manager, Corporate and
Brand Communications
514-956-6120

General inquiries

514-956-6200
1-800-363-6364

Press Releases

Archives: Search / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010

200920082007

May 26, 2016

- FDA decisions on the investigational fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide and investigational lixisenatide anticipated in Q3 2016 -

More
May 24, 2016

As 8 in 10 Canadian GPs identify the need for new cholesterol treatment options, Canadian Patients now have accessto PRALUENT™ MONTREAL, May 24, 2016 /CNW Telbec/ - Sanofi Canada is pleased to...

More
May 9, 2016

Iveta Demirova, 16, student at New Westminster Secondary School in British Columbia, Recognized for Novel HIV-1 Treatment OTTAWA, May 9, 2016 /CNW Telbec/ - Iveta Demirova from New Westminster...

More
Feb 23, 2016

Sanofi (EURONEXT : SAN and NYSE : SNY) announced today that the License and Development Agreement between Sanofi and kaléo, formerly Intelliject Inc., the developer of Auvi-Q® and Allerject®...

More
Feb 4, 2016

Montreal, Quebec – February 4, 2016 – Sanofi Canada is pleased to announce that it has once again been named one of Montreal’s Top Employers, a designation that recognizes its consistent...

More
Dec 2, 2015

Following the October 28, 2015 voluntary recall by Sanofi-aventis Canada Inc. (Sanofi Canada) of all lots of Allerject® epinephrine auto-injectors of both the 0.15mg/0.15mL and 0.30mg/0.3mL...

More
Nov 9, 2015

Sanofi Canada is proud to announce that it has been named one of Canada's Top 100 Employers by a prestigious annual competition that recognizes the nation's best places to work. The competition is...

More
Oct 28, 2015

Sanofi-aventis Canada Inc. (Sanofi Canada) is recalling all Allerject® (epinephrine injection, USP). The voluntary recall involves all Allerject currently on the market and includes both the 0.15...

More
Sep 2, 2015
Local Team Implements Program with Support from Allerject®

Sussex, NB, Sept. 2, 2015 – The Town of Sussex and surrounding area (population: approximately 35,000) in New Brunswick might well be the very first community in Canada – and perhaps North...

More
Sep 1, 2015

- Largest Phase 3 analysis of patients with familial hypercholesterolemia showed adding Praluent to standard-of-care therapy reduced LDL-cholesterol by an average 56 percent compared to...

More
 

Corporate information

CORPORATE INFORMATION